Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
== Death == Eastlack died at the Inglis House for the Incurables—a care home dedicated to attending low-income, physically disabled individuals. As he approached the later stages of his life, he required assistance to stand and used a cane to be able to shuffle. During his time there, he broke his right leg, and the broken leg healed at an extremely odd angle. He spent the last years of his life being permanently disabled and bedridden and in severe and constant pain. He eventually developed bronchial pneumonia from the physical inactivity of his body. Due to the ossification of his ribs, his lungs could only expand very little, and this made it almost impossible for him to even cough. Because he had extreme difficulty in being able to cough, even more bronchial fluid filled his lungs, eventually making it difficult for him to breathe. Near the time of his death, Eastlack told his elder sister, Helene, that he desired to donate his body and medical records to research, so that the disease may be further investigated and understood. On November 11, 1973, aged 39, Eastlack died of severe bronchial pneumonia.
A sarcomere (Greek σάρξ sarx "flesh", μέρος meros "part") is the smallest functional unit of striated muscle tissue. It is the repeating unit between two Z-lines. Skeletal muscles are composed of tubular muscle cells (called muscle fibers or myofibers) which are formed during embryonic myogenesis. Muscle fibers contain numerous tubular myofibrils. Myofibrils are composed of repeating sections of sarcomeres, which appear under the microscope as alternating dark and light bands. Sarcomeres are composed of long, fibrous proteins as filaments that slide past each other when a muscle contracts or relaxes. The costamere is a different component that connects the sarcomere to the sarcolemma. Two of the important proteins are myosin, which forms the thick filament, and actin, which forms the thin filament. Myosin has a long fibrous tail and a globular head that binds to actin. The myosin head also binds to ATP, which is the source of energy for muscle movement. Myosin can only bind to actin when the binding sites on actin are exposed by calcium ions. Actin molecules are bound to the Z-line, which forms the borders of the sarcomere. Other bands appear when the sarcomere is relaxed. The myofibrils of smooth muscle cells are not arranged into sarcomeres.
==== Martyrs ==== The decision as to whether martyrs had died for their faith in Christ and the consequent permission of veneration lay originally with the bishop of the place in which they had borne their testimony. The bishop inquired into the motive of the person's death and, on finding they had died a martyr, sent their name with an account of their martyrdom to other churches, especially neighboring ones, so that, in the event of approval by their respective bishops, the cultus of the martyr might extend to their churches also and that the faithful, as is said of Ignatius of Antioch in the "Acts" of his martyrdom "might hold communion with the generous martyr of Christ" (generoso Christi martyri communicarent). Martyrs whose cause, so to speak, had been discussed, and the fame of whose martyrdom had been confirmed, were known as proved (vindicati) martyrs. That word probably did not antedate the fourth century, when it was introduced into the Church at Carthage; but the fact is certainly older. In the earlier ages, therefore, this veneration was entirely local and passed from one church to another with the permission of their bishops. This is clear from the fact that in ancient Christian cemeteries there are found paintings of only those martyrs who had suffered in that neighborhood. It explains, also, the almost universal veneration very quickly paid to, e.g., Lawrence, Cyprian, and Sixtus II, who were killed by the Roman Emperor Valerian.
Glucose-6-phosphate dehydrogenase deficiency (G6PDD), also known as favism, is the most common enzyme deficiency anemia worldwide. It is an inborn error of metabolism that predisposes to red blood cell breakdown. Most of the time, those who are affected have no symptoms. Following a specific trigger, symptoms such as yellowish skin, dark urine, shortness of breath, and feeling tired may develop. Complications can include anemia and newborn jaundice. Some people never have symptoms. It is an X-linked recessive disorder that results in defective glucose-6-phosphate dehydrogenase enzyme. Glucose-6-phosphate dehydrogenase is an enzyme that protects red blood cells, which carry oxygen from the lungs to tissues throughout the body, from reactive oxygen species. An enzyme defect results in the premature breakdown of red blood cells. This destruction of red blood cells is called hemolysis. Red blood cell breakdown may be triggered by infections, certain medication, stress, or foods such as fava beans. Depending on the specific mutation the severity of the condition may vary. Diagnosis is based on symptoms and supported by blood tests and genetic testing. Affected persons must avoid dietary triggers, notably fava beans. This can be difficult, as fava beans may be called "broad beans" and are used in many foods, whole or as flour. Falafel is probably the best known, but fava beans are often used as filler in meatballs and other foods. Treatment of acute episodes may include medications for infection, stopping the offending medication, or blood transfusions.
In 2004, John L. Helgerson, the Inspector General of the Central Intelligence Agency (CIA), conducted an internal review of the agency's pre-9/11 performance and was harshly critical of senior CIA officials for not doing everything possible to confront terrorism. According to Philip Giraldi in The American Conservative, Helgerson criticized their failure to stop two of the 9/11 hijackers, Nawaf al-Hazmi and Khalid al-Mihdhar, as they entered the United States and their failure to share information on the two men with the FBI. In May 2007, senators from both major U.S. political parties (the Republican and Democratic parties) drafted legislation to make the review public. One of the backers, Senator Ron Wyden said, "The American people have a right to know what the Central Intelligence Agency was doing in those critical months before 9/11." The report was released in 2009 by President Barack Obama.
Sources: en.wikipedia.org
== Single particle == In November 2017, an international team of scientists isolated a single proton in a Penning trap in order to measure its magnetic moment to the highest precision to date. It was found to be 2.79284734462(82) nuclear magnetons. The CODATA 2018 value matches this.
=== Pharmacokinetics === Flurpiridaz (18F) has peak blood radioactivity at 2.3 minutes after administration, followed by a rise and plateau. Distribution of this radiopharmaceutical is complex, as it transfuses into the liver (13%), kidneys (9%), brain (8%) and epicardium (3%, radioactivity retains for 1 hour after administration). Full clearance is achieved within 48 hours. Only metabolites of flurpiridaz are excreted, mainly in urine and feces. Flurpiridaz metabolises into many different polar metabolites. There are no differences in pharmacokinetics caused by age, sex, body mass index (BMI), diabetic status, Clid Pugh A hepatic impairment and renal impairment at eGFR≥19-89 mL/min.
==== Development of GLP-1-based therapies ==== During his tenure as chief scientific officer at Novo Nordisk, Thomsen played a significant role in the development of GLP-1-based therapies, including Ozempic and Wegovy. In the early 1990s, despite skepticism from company leadership regarding the potential of obesity treatments, Thomsen advocated for focusing on obesity as a significant health issue. This strategic direction led to the development of Ozempic, approved for Type 2 diabetes treatment in 2017, and Wegovy, approved for weight loss in 2021. Both medications are based on semaglutide, a GLP-1 receptor agonist designed to regulate blood sugar levels and appetite.
Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the structure of the neuropeptide somatostatin, which is an endogenous hormone found in the human body. The somatostatin receptors are G protein-coupled receptors. Somatostatin receptor subtypes in humans include sstr1, 2A, 2 B, 3, 4, and 5. While normally expressed in the gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS), they are expressed in different types of tumours. The predominant subtype in cancer cells is the ssrt2 subtype, which is expressed in neuroblastomas, meningiomas, medulloblastomas, breast carcinomas, lymphomas, renal cell carcinomas, paragangliomas, small cell lung carcinomas, and hepatocellular carcinomas. As a radiopharmaceutical compound that is selective for somatostatin receptors, there is research being done for these radiolabeled compounds to act as diagnostic tests in PET scans for neuroendocrine tumors and other tumors not previously targeted with radiolabeled somatostatin receptor agonists, and to act as radiopharmaceutical therapeutic compound, more specifically to conduct peptide radionuclide receptor therapy. Some non-radiopharmaceutical compounds that are developed as competitive inhibitors of somatostatin, such as the hormone antagonist cyclosomatostatin.
The rise has been exacerbated by the number of people sent to prison for their participation in the 2024 United Kingdom riots and the August Bank Holiday weekend, during which prisoners are not traditionally released. At one point during the preceding week, the number of spare prison places is believed to have fallen to less than 100. 31 August – A yellow weather warning for heavy rain and thunderstorms is issued for the following day for much of England and parts of east Wales.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.